AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05052749 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Resistance Training (HIRT)
Description: High Intensity Resistance Exercises Supervised High Intensity Resistance Training with 15 minutes of cycling as a warm-up activity then HIRT through Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
Study NCT05052749 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-moderate Resistance Exercise Training
Description: Supervised Low-moderate Resistance Training with 15 minutes of cycling as a warm-up activity then Quadriceps drill, Squats, Lunges, Leg press, Biceps curls and Deadlift with 120 seconds of rest interval between each set of exercise and between exercises will be performed by the participants with appropriate cool down through generalized stretching exercises. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks respectively.
Study NCT05268497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine
Description: Esketamine will be self-administered as nasal spray.
Study NCT05268497 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Clinician-directed CBT supplemented by the Mindset app will be administered.
Study NCT05268497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant
Description: Antidepressant will be administered orally.
Study NCT05291806 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference Product
Description: This intervention is based on white rice.
Study NCT05291806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain product Dose A
Description: This wholegrain intervention contains whole cereal kernels.
Study NCT05291806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain product Dose B
Description: This wholegrain intervention contains whole cereal kernels.
Study NCT05291806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain product Dose A, cut kernels
Description: This wholegrain intervention contains cut cereal kernels.
Study NCT05273177 — intervention group
Intervention type: OTHER
Intervention: Chronic ankle instability
Description: Persistent condition of ankle instability after a first ankle sprain episode.
Study NCT05871190 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: İnjectable platelet rich fibrin
Description: I-PRF is a type of platelet-rich fibrin (PRF) product obtained from the patient's own blood. PRF is a kind of tissue regeneration product of blood, rich in platelets, growth factors and cellular components.
Study NCT05871190 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gingivectomy anad gingivoplasty
Description: leveling and regulation of the gingiva
Study NCT05871190 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gingivectomy anad gingivoplasty
Description: leveling and regulation of the gingiva
Study NCT06009263 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain.
Study NCT06009263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open chain segmental control
Description: Application of open chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain.
Study NCT06009263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed chain segmental control
Description: Application of closed chain segmental control exercises As well as, application of ultrasound and transcutaneous electrical nerve stimulation TENS for mechanical low back pain.
Study NCT06546514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breath Exercise
Description: It was provided by the researcher that the patients performed 5 repetitions of 10 breathing exercises every 3 hours a day, between 09:00am and 21:00pm, 1 day before the surgery, on the day of surgery and on the first day after surgery.
Study NCT05155488 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06541340 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified strategy
Description: Modified preoperative biliary drainage strategy with prealbumin as the main indicator
Study NCT06541340 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional strategy
Description: Traditional preoperative biliary drainage strategy with total bilirubin as the main indicator
Study NCT05624697 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: sticky bone housed in PEEK Shell
Description: Patient specific Sticky Bone/Implant housing PEEK shell in Anterior Atrophic Maxilla
Study NCT05998317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: At-night Dexamethasone
Description: Patients in the intervention group will receive intravenous 8 mg dexamethasone at night before surgery. The time of dexamethasone administration will be recorded. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Study NCT05998317 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: At-induction Dexamethasone
Description: Patients in the control group will receive intravenous 8 mg dexamethasone just before or at the induction of anesthesia. The dexamethasone ampule will be diluted in a 10 ml syringe and given in at least one minute to avoid unpleasant sensation in injection.
Study NCT05612802 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: IGF-1
Description: We need to diagnose acute kidney injury in the early postoperative period. The markers examined so far do not provide enough information to diagnose acute kidney injury early. For this reason, many different biomarkers are used in the early diagnosis of acute kidney injury in many parts of the world. Thanks to our research, we can recognise the development of acute kidney injury at an early stage and determine whether a previously unused biomarker (IGF-1) is effective in the early diagnosis of acute kidney injury.
Study NCT05103839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gentle Yoga
Description: Yoga classes are twice a week for up to 10 weeks with a trained yoga instructor at a location in the community. Classes will last up to 75 minutes.
Study NCT06068283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOTUS mHealth Intervention Group
Description: A mobile, WebApp-based intervention comprised of tips for HIV prevention, a community wall for peer interaction and support, HIV prevention monitoring and reminders, guided discussions with a health care professional, a resource database, and a personalized profile. Intervention components are designed to promote HIV prevention service use, reduce stigma and improve social support, coping strategies, and positive affect.
Study NCT06068283 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LOTUS Control Group
Description: Access to an information-only website with content on HIV transmission, PrEP, harm reduction, and resources for women.
Study NCT05008393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJS-539 Dose 1
Description: Patients will receive PJS-539 dose 1 daily for 10 days.
Study NCT05008393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PJS-539 Dose 2
Description: Patients will receive PJS-539 Dose 2 daily for 10 days.
Study NCT05008393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo daily for 10 days.
Study NCT05031637 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment of BP by using night-time BP
Description: titration of BP medications to target according to night-time SBP
Study NCT05031637 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: treatment of BP by using daytime BP
Description: titration of BP medications to target according to daytime SBP
Study NCT05388149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Neratinib administered as 40mg tablets
Study NCT05200117 — intervention group
Intervention type: DEVICE
Intervention: Pregnolia System
Description: The cervical stiffness is measured with the Pregnolia System three times over a two-day period.
Study NCT06507904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osivelotor
Description: A medicine to treat sickle cell disease.
Study NCT06507904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine is a marketed medicine which decreases the amount of acid made in the stomach and is used to prevent and treat heartburn.
Study NCT04633239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO
Study NCT04633239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT04633239 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT04633239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT06583447 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Calorie-restricted diet (CRD)
Description: Standardized lifestyle interventions for all obese children and their parents will be constructed by endocrinologists and dietitians to increase physical activity and healthy eating habits. Physical activity interventions include decreasing time spent in sedentary activities, increasing the amount of physical activity, and recommending at least 60 minutes of moderate-intensity exercise per day. Individualized dietary counseling is provided to address the comorbidities in obese children.~Based on the standardized lifestyle intervention, the study subjects in the control group will be treated with CRD. Total daily energy intake will be restricted to 80% of the energy requirement for each age group in the Dietary Reference Intakes of Nutrients for Chinese Residents DRIs 2013. A daily food diary will be kept for at least one weekday and one weekend per week.
Study NCT06583447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Description: Based on the standardized lifestyle intervention mentioned by the calorie-restricted diet (CRD) intervention, TRE is administered to the study subjects in the intervention group. The eating window is limited to 12 hours per day, with the last meal no later than 7:00 p.m., and the study subjects are free to choose their eating window. Energy intake is not restricted during the eating period, and calorie-free, sugar-free beverages (water, tea, coffee) are allowed during the fasting period. A daily food diary will be kept for at least one weekday and one weekend per week.
Study NCT06242418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI
Description: Eight cycles of FOLFOXIRI: Oxaliplatin 85mg/m2 ivgtt over 2 hours on day 1, Irinotecan 165mg/m2 ivgtt over 90 minutes on day 1, Calcium folinate 400mg/m2 ivgtt over 2 hours on day 1, 5-Fluorouracil 2400mg/m2 civ48h; Each cycle lasts for 2 weeks.
Study NCT06242418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: Five cycles of XELOX: Oxaliplatin 130mg/m2 on day 1, Capecitabine 1000mg/m2 bid from day 1 to day 14; Each cycle lasts for 3 weeks.
Study NCT05112289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Brain Neuroimaging
Description: Non-invasive magnetic resonance imaging sequences will investigate metabolic signatures unique to migraine WMH. Imaging data will be used for development of artificial intelligence (AI) algorithms to classify the cause of WMHs.
Study NCT06066528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Survodutide
Description: once weekly subcutaneous injection
Study NCT06066528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once weekly subcutaneous injection
Study NCT06648161 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labor Mirror
Description: The labor mirror used in the second stage of labor allows the mother and midwife to observe the descent and birth of the baby during vaginal delivery and provides instant visualization of progress for the mother and midwife, especially in water births or water births
Study NCT05256771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EMS
Description: Abdominal muscle stimulation using EMS
Study NCT05256771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1064 nm diode laser
Description: Adipose tissue heating using 1064 nm diode laser
Study NCT05256771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RF/PEMF
Description: Collagen re-modelling and reduction in subcutaneous fat using RF/PEMF
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Livmoniplimab
Description: Intravenous (IV) Solution
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: Intravenous (IV) Solution
Study NCT05274308 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Blood sampling from all eligible transplantation patients according to the protocol
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Intravenous (IV) Solution
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Intravenous (IV) Solution
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Intravenous (IV) Solution
Study NCT06109272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tremelimumab
Description: Intravenous (IV) Solution
Study NCT05366218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Antibody vaccination
Study NCT05925114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-309309
Description: Administered as oral capsules
Study NCT05925114 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as an oral capsule that looks identical to S-309309 capsule
Study NCT06177301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GX
Description: Tislelizumab：200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine：1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles. Capecitabine: 1000mg/m2, bid，po, d1-14, q3; treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.
Study NCT06177301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with GP
Description: Tislelizumab: 200mg vgtt，q3w；treatment until disease progression, patients withdrawal of informed, or intolerable toxicity.~Gemcitabine: 1000mg/m2, vgtt, d1,8, q3w, repeat 4-6 cycles； Cisplatin: 80mg/m2, ivgtt, d1 (high-dose cisplatin antiemetic and hydration regimen), q3w，repeat 4 \~ 6 cycles.
Study NCT06083675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Administered as oral tablets.
Study NCT06083675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Administered as oral tablets.
Study NCT06083675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Administered as oral tablets.
Study NCT04956263 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YG1699
Description: YG1699 is a novel investigational dual inhibitor of sodium-dependent glucose cotransporters, SGLT1 and SGLT2, indicated as an adjunct to diet and exercise to improve glycemic control and weight loss in adults with T2DM. A subsequent indication will be developed for YG1699 to improve glycemic control in adults with T1DM.~The proposed dosage form is a yellow, film-coated tablet for oral administration. The proposed tablet strengths for the current clinical research are 5 mg and 25 mg. The tablets are packaged in high-density polyethylene (HDPE) bottles with HDPE caps and desiccant inserters. Each HDPE bottle contains 30 tablets of drug product.~The study drug YG1699 is manufactured by Youngene Therapeutics Inc., Ltd., China.
Study NCT04956263 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Farxiga® is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. Faxiga® is available as a film-coated tablet for oral administration containing the equivalent of 5 mg dapagliflozin as dapagliflozin propanediol and the following inactive ingredients: microcrystalline cellulose, anhydrous lactose, crospovidone, silicon dioxide, and magnesium stearate. In addition, the film coating contains the following inactive ingredients: polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, and yellow iron oxide.
Study NCT05297253 — intervention group
Intervention type: DEVICE
Intervention: telescopic overdenture
Description: fixed implant retained prostheses
Study NCT05449847 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood Sampling
Description: Blood sampling under a complete aseptic conditions
Study NCT06310798 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inter-professional team test
Description: Digital Platform Support is used to improve communication and collaboration between the different stakeholders involved in the care of older adults. This platform allows for the sharing of oral health assessments, plans, and recommendations, ensuring all parties have access to the same information and can contribute to the care planning process.~Person-Centered, Three-Step Model:~Initial oral health assessments conducted by dental professionals, A person-centered planning process where the needs and preferences of the older adults are prioritized, The implementation of tailored oral health care plans, emphasizing shared decision-making and the active involvement of older adults in their care.~Educational Component: An important element of the intervention is the provision of a two-day course for nursing and dental staff.
Study NCT05458830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Barrier Reduction Intervention
Description: After selecting a barrier in the barrier survey, participants receive tailored information with the purpose of addressing common concerns and misconceptions about the helpline.
Study NCT05458830 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Plain advisory text
Description: Care as usual
Study NCT06270017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: rsponse evaluation in zebrafish embryo model
Study NCT05767242 — intervention group
Intervention type: OTHER
Intervention: Electrophysiological recording
Description: Investigation of early neural markers using electrophysiology at 6-12-24 months
Study NCT05767242 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral assessment
Description: Individual behavioral assessment at later ages (3, 4.5, 6, and 8 years)
Study NCT05725733 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
Study NCT05725733 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: The participant will walk for 3-minutes at this speed as a warming up period. After these 3-minutes, the speed will be increased gradually up to 5-6 km/minute under the supervision of parents and therapist. The children will perform 10-minute running at this speed. After this, the cooling down exercise will be performed for 3-minutes. The speed will be decreased for 2 km/ minute and gradually stop.
Study NCT06199206 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Theraputic Play
Description: Before the procedures, therapeutic games will be played with the children and people of the intervention groups with eLPi dolls and other play materials prepared in accordance with anatomy. The parent will be with the child during this game, which will be played in his/her own room.
Study NCT04848103 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shockwave therapy
Description: Radial extracorporeal shockwave therapy group include Therapeutic modality(Transcutaneous electrical nerve stimulation \[TENS\], Microwave thermotherapy, and Superficial heat therapy), Range of motion exercise(Continuous passive motion and Active range of motion exercise).
Study NCT04885634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Subcutaneous injection of Semaglutide 2.4 mg once weekly
Study NCT04885634 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of volume-matched placebo once weekly